Pharmacyclics (PCYC) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Pharmacyclics (PCYC)

An SI Board Since August 1996

Posts	SubjectMarks	Bans	Symbol
717	41	0	PCYC

Emcee: Doug Meetmer	Type: Unmoderated

Introduction Market Data Compact

Please also see discussions about PCYC under QLT area.

Pharmacyclics is a company with three products in clinical development
and multiple compounds in preclinical development. Their products are:

Gd-Tex (gadolinium texophyrin), a radiation sensitizer. This product
is in Phase I trials, which are still open for enrollment. They are
studying effects on brain metastases, as well as looking at MDT's
(maximum tolerable dose).

Lu-Tex (lutetium texaphyrin PCI-0123), a light activated drug being
studied for treatment of various cutaneous tumors, including Kaposis
Sarcoma, melanoma, breast CA, and others. It is in Phase I trials,
the interim results of which looked very favorable for both efficacy
and toxicity. In fact, it could be a very important compound when and
if they demonstrate its efficacy in trials, because the drug has a fairly
short half-life, which limits its toxicity.

Gadolite oral suspension, an MRI contrast agent for the GI tract. This
is in Phase III trials and a NDA has been filed.

I believe they will compete in a difficult but very promising market.
The real question will be what , if any, advantages will Lu-Tex
have over products being studied by QLT and PDT. The CEO of PCYC is
Rich Miller who founded IDEC pharmaceuticals and he is supposedly
a very bright guy and whatever he touches seems to work (both
scientifically and for the shareholders).

I am not a stock promoter nor am I a principal of the company,
but I have been watching PCYC for several months and just
bought some shares due to the recent weakness in its stock price, and
because of the potential for its products.

I would love to keep and ongoing discussion about this company.

Doug

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
717	Blood. 2015 Apr 2. pii: blood-2015-01-621391. [Epub ahead of print] Selinexor i	scaram(o)uche	-	4/7/2015
716	Story about the President of Pharmacyclics being the largest donor to Scientolog	Chris12	-	1/29/2013
715	You were more than right. $60 though?	Wayners	-	7/18/2012
714	ok, so over a longish range these guys have been steady. expecting that they wil	marketfriends	-	2/8/2012
713	ok, this might interest some people who have been thinking about PCYC. marketfr	marketfriends	-	2/6/2012
712	PCYC will going up very soon. What do you think??	dondon26	-	5/2/2007
711	What about the compassionate conservative panel (CCAC)?	rkrw	-	4/4/2007
710	Here's hoping it is accepted and they draw the neutraceuticals panel.	keokalani'nui	-	4/4/2007
709	PCYC... I file on you. Pharmacyclics to file cancer drug over FDA protest Wed A	kenhott	-	4/4/2007
708	<i>I wonder what this is about.</i> Hmm. Lot of shares short.	Steve Lokness	-	4/3/2007
707	I wonder what this is about. If the BoD staged a coup or they dump the texaphri	keokalani'nui	-	4/3/2007
706	I just listened to Cowen and dumped the few shares I bought after the RTF. The	keokalani'nui	-	3/15/2007
705	Hi mcbio I do not follow them anymore. Have no insight into what they are doin	John McCarthy	-	3/3/2007
704	Anyone follow PCYC anymore? I don't have a position but am considering give	mcbio	-	3/3/2007
703	Pharmacyclics Announces Presentation and Publication of Preliminary Results Eval	John McCarthy	-	12/12/2005
702	RE "nice action....." For sure! I seem to remember PCYC crashing fro	EACarl	-	3/2/2004
701	Nice action today. Message 19869718 Marc	JMarcus	-	3/2/2004
700	Any thoughts on the enrollment period for the current Phase 3 SmartTrial. I be	Gary105	-	1/21/2004
699	It is an interesting case. I would like to know why they saw so "good"	Icebrg	-	1/18/2004
698	(editing, here..... Marc, I meant to address this post to you, just to let yo	scaram(o)uche	-	1/18/2004
697	Response to motexafin gadolinium and ionizing radiation of experimental rat pros	Icebrg	-	1/16/2004
696	Marc >>It just so happens that NSCLC metastasizing to the brain provides	Icebrg	-	1/16/2004
695	The CEO's letter to stockholders from the 2003 Annual Report provides a good	JMarcus	-	1/16/2004
694	Erik, for the moment I'm pingponging between here and the Biotech Valuation	JMarcus	-	1/16/2004
693	>>Journal of Clinical Oncology>> The big Question is "Why only	Icebrg	-	1/16/2004

Go to reply# or date (mm/dd/yy):